Tom Lynch outlines his comeback strategy for Bristol-Myers’ badly bruised R&D organization
When Tom Lynch took the top R&D job at Bristol-Myers Squibb, he got one of the best — and at the same time, one of the hardest — jobs in biotech.
It was one of the best because Bristol-Myers built what is widely considered one of the most innovative research groups for a biopharma of its size, in a heavyweight class not known for homemade breakthroughs. It was one of the hardest because the group had just derailed, giving up its first-place position in immuno-oncology in a hard fall on a misguided late-stage effort on lung cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
